TrialX, a NYC-based life sciences technology company has launched Covid Labs, an open platform made up of computer scientists, informaticians, data scientists and designers that are banding together across organizations to solve unique challenges posed by the COVID-19 pandemic. The initiative aims to enable individuals, healthcare agencies, life sciences companies and governments to leverage the power of data, web and mobile technologies to understand and tackle this global crisis.
Dr. Sharib Khan, Co-founder and CEO of TrialX, who kickstarted this initiative mentioned, “As we face a once in a lifetime pandemic, the speed at which the COVID-19 has spread globally, requires the same agility in how we respond to it. Whether it be social distancing to ‘flatten the curve’, or staying up all night, to hack open data sets or re-package existing code, the crisis is a rallying cry for all of us to pitch in.”
In the spirit of “hacking” the pandemic, the lab has already launched several projects including CovidClinicalTrials.com, a global clinical trials tracker displaying a dashboard of all ongoing/planned COVID clinical trials and new treatments and vaccines being investigated by sponsors and research universities. The website provides resources for patients to find and contact research centers near them. The lab has also created a cross-platform symptom tracker app based on Apple’s ResearchKit and Android ResearchDroid to allow investigators and researchers to launch research studies for tracking symptoms related to COVID-19. To increase awareness, the lab hosted a discussion on living with Covid-19 on the CureTalks online radio show that features leading experts and patient advocates.
The lab has an open invite to individuals with a passion for life sciences, public health, data and technology to leverage their skills to hack this pandemic.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.